JPH07285860A - Ｌ−ｄｏｐａエステルの組成物 - Google Patents

Ｌ−ｄｏｐａエステルの組成物

Info

Publication number
JPH07285860A
JPH07285860A JP5328941A JP32894193A JPH07285860A JP H07285860 A JPH07285860 A JP H07285860A JP 5328941 A JP5328941 A JP 5328941A JP 32894193 A JP32894193 A JP 32894193A JP H07285860 A JPH07285860 A JP H07285860A
Authority
JP
Japan
Prior art keywords
dopa
ethyl ester
acid
pharmaceutical composition
dopa ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP5328941A
Other languages
English (en)
Japanese (ja)
Inventor
Isaac Milman
アイザック・ミルマン
Alexander Veinberg
アレクサンダー・ベインベルグ
Daphne Atlas
ダフン・アトラス
Eldad Melamed
エルダド・メラメド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Teva Pharmaceutical Industries Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Teva Pharmaceutical Industries Ltd
Publication of JPH07285860A publication Critical patent/JPH07285860A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
JP5328941A 1992-12-24 1993-12-24 Ｌ−ｄｏｐａエステルの組成物 Ceased JPH07285860A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/995,847 US5354885A (en) 1992-12-24 1992-12-24 Process for preparing ethyl ester of L-DOPA
US995847 1992-12-24

Publications (1)

Publication Number Publication Date
JPH07285860A true JPH07285860A (ja) 1995-10-31

Family

ID=25542272

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5328941A Ceased JPH07285860A (ja) 1992-12-24 1993-12-24 Ｌ−ｄｏｐａエステルの組成物

Country Status (20)

Country Link
US (2) US5354885A (de)
EP (2) EP0867179B1 (de)
JP (1) JPH07285860A (de)
CN (1) CN1083262C (de)
AT (2) ATE178793T1 (de)
AU (1) AU684053B2 (de)
CA (1) CA2112160A1 (de)
CY (1) CY2214B1 (de)
DE (2) DE69329400T2 (de)
DK (2) DK0867179T3 (de)
ES (2) ES2150294T3 (de)
FI (1) FI107994B (de)
GR (2) GR3030073T3 (de)
HU (1) HU218906B (de)
IL (1) IL108147A (de)
LV (1) LV12766B (de)
NO (1) NO305932B1 (de)
NZ (1) NZ250541A (de)
PT (1) PT867179E (de)
ZA (1) ZA939573B (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510686A (ja) 2002-12-19 2006-03-30 ビーディーディー ベロリーナ ドラッグ デベロプメント ゲーエムベーハー 重水素化カテコールアミン誘導体ならびにそれらの化合物を含有する医薬品
JP2007504143A (ja) * 2003-08-29 2007-03-01 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
JP2007508313A (ja) * 2003-10-08 2007-04-05 マリンクロッド・インコーポレイテッド メチルフェニデート溶液および関連する投与および製造方法
JP2009001588A (ja) * 1996-10-13 2009-01-08 Neuroderm Ltd パーキンソン病を治療するための方法並びに装置

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
AU7669496A (en) * 1995-11-03 1997-05-22 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
CA2236368C (en) * 1995-11-06 2001-10-23 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
AU768154B2 (en) * 1996-10-13 2003-12-04 Neuroderm Ltd Treatment of Parkinson's disease
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
BR9908713A (pt) 1998-03-16 2000-11-21 Somerset Pharmaceuticals Inc Uso de selegilina ou desmetil-selegilina para tratamento de feridas, queimaduras e danos dermatológicos
JP2002529407A (ja) * 1998-11-10 2002-09-10 テバ ファーマシューティカル インダストリーズ リミティド Ｌ−ｄｏｐａエチルエステル含有分散性組成物
EP1137626A4 (de) * 1998-11-10 2002-07-17 Teva Pharma Verfahren zur herstellung von l-dopa-ethylester
RU2157196C1 (ru) * 1999-06-17 2000-10-10 Васильев Виталий Николаевич Фармацевтическая композиция в.н. васильева для восстановления функции симпатико-адреналовой системы, способ оценки индивидуальной эффективности этой композиции для терапии пациентов
RU2173150C1 (ru) * 2000-06-27 2001-09-10 Васильев Виталий Николаевич Фармацевтическая композиция для биокоррекции симпатико-адреналовой системы
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
AU2002340470A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
US20030135065A1 (en) * 2001-11-13 2003-07-17 Ramy Lidor-Hadas Process for the production of L-DOPA ethyl ester
HUE031167T2 (hu) 2002-03-20 2017-07-28 Civitas Therapeutics Inc A levodopa pulmonális bejuttatása
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
EP1596808A4 (de) * 2003-02-07 2007-04-04 Yissum Res Dev Co L-dopa-amidderivate und ihre verwendung
EP1622450A4 (de) * 2003-04-25 2009-11-18 Endo Pharmaceuticals Solutions Verfahren zur förderung des durchschlafens durch verabreichung von trospiumchlorid
KR100525358B1 (ko) * 2003-08-21 2005-11-04 주식회사 이엔에프테크놀로지 카르복실 벤조트리아졸 알킬에스테르의 제조방법
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
BRPI0708071A8 (pt) * 2006-02-17 2017-12-26 Birds Pharma Gmbh Berolina Innovative Res & Development Services Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
CN101623278B (zh) * 2008-07-09 2013-02-27 北京德众万全药物技术开发有限公司 一种含有左旋多巴和盐酸苄丝肼的药物组合物
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
WO2017032874A1 (en) * 2015-08-27 2017-03-02 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
EP3518920A1 (de) 2016-09-29 2019-08-07 Berlirem GmbH L-dopa-derivate zur behandlung von neurologischen erkrankungen
PT4039093T (pt) 2021-02-09 2023-10-20 Biobab R&D S L Star Método e utilização de enantiómeros de 3,4-dihidroxifenilalanina (dopa) para aumentar a atratividade das plantas para insetos benéficos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716958B (en) * 1970-10-30 1973-01-31 Hoffmann La Roche Phenylalanine amides
US3803120A (en) * 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009001588A (ja) * 1996-10-13 2009-01-08 Neuroderm Ltd パーキンソン病を治療するための方法並びに装置
JP2006510686A (ja) 2002-12-19 2006-03-30 ビーディーディー ベロリーナ ドラッグ デベロプメント ゲーエムベーハー 重水素化カテコールアミン誘導体ならびにそれらの化合物を含有する医薬品
JP2015178537A (ja) * 2002-12-19 2015-10-08 インファール・アクティエンゲゼルシャフト 重水素化カテコールアミン誘導体ならびにそれらの化合物を含有する医薬品
USRE46629E1 (en) 2002-12-19 2017-12-12 Teva Pharmaceuticals International Gmbh Deuterated catecholamine derivatives and medicaments compromising said compounds
JP2007504143A (ja) * 2003-08-29 2007-03-01 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
JP2007508313A (ja) * 2003-10-08 2007-04-05 マリンクロッド・インコーポレイテッド メチルフェニデート溶液および関連する投与および製造方法

Also Published As

Publication number Publication date
NO934768L (no) 1994-06-27
ES2150294T3 (es) 2000-11-16
FI935847A0 (fi) 1993-12-23
NO305932B1 (no) 1999-08-23
ES2132170T3 (es) 1999-08-16
HU9303748D0 (en) 1994-04-28
CN1083262C (zh) 2002-04-24
LV12766A (lv) 2001-12-20
ZA939573B (en) 1994-08-11
GR3034867T3 (en) 2001-02-28
EP0867179B1 (de) 2000-09-06
IL108147A0 (en) 1994-04-12
AU684053B2 (en) 1997-12-04
DE69324466T2 (de) 1999-11-25
CN1094950A (zh) 1994-11-16
LV12766B (en) 2002-03-20
EP0610595A2 (de) 1994-08-17
CA2112160A1 (en) 1994-06-25
HK1012577A1 (en) 1999-08-06
US5525631A (en) 1996-06-11
DK0867179T3 (da) 2000-11-06
NO934768D0 (no) 1993-12-22
FI107994B (fi) 2001-11-15
FI935847L (fi) 1994-06-25
PT867179E (pt) 2000-12-29
HU218906B (hu) 2000-12-28
EP0610595A3 (en) 1994-09-21
NZ250541A (en) 1995-12-21
ATE178793T1 (de) 1999-04-15
IL108147A (en) 1998-09-24
US5354885A (en) 1994-10-11
DE69324466D1 (de) 1999-05-20
DK0610595T3 (da) 1999-10-25
AU5257793A (en) 1994-07-07
DE69329400T2 (de) 2001-01-18
EP0867179A1 (de) 1998-09-30
CY2214B1 (en) 2002-11-08
EP0610595B1 (de) 1999-04-14
ATE196081T1 (de) 2000-09-15
DE69329400D1 (de) 2000-10-12
GR3030073T3 (en) 1999-07-30
HUT68498A (en) 1995-06-28

Similar Documents

Publication Publication Date Title
US5354885A (en) Process for preparing ethyl ester of L-DOPA
US5607969A (en) L-DOPA ethyl ester to treat Parkinson's disease
RU2128160C1 (ru) Трометаминная соль (+)-(s)-2-(3-бензоилфенил)пропионовой кислоты, способ ее получения, фармацевтическая композиция
KR101411422B1 (ko) 중수소화 카테콜아민 유도체 및 이를 포함하는 의약품
BG64746B1 (bg) Състав за орално приложение, съдържащ левосимендан
EP0579681B1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
DE2851435C2 (de) Substituierte Amide und Dipeptide des L und DL-p-Hydroxyphenylglycins, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP1613571B1 (de) Deuterierte catecholaminderivate sowie diese verbindungen enthaltende arzneimittel
DE1931240A1 (de) Aminoalkancarbonsaeuren
AU6924294A (en) Heterocyclic chemistry
US6218566B1 (en) Process for manufacturing of L-DOPA ethyl ester
HK1012577B (en) Composition of l-dopa esters
EP2647618A1 (de) Neuartige Polymorphe und Salze
FR3067711A1 (fr) Inhibiteurs de la catechol-o-methyl-transferase (comt)
FR2470133A1 (fr) Nouveaux sels d'addition d'acides d'alcaloides de l'ergot et d'alcaloides du dihydro-ergot physiologiquement acceptables et amorphes aux rayons x, utiles comme medicaments et procede de leur preparation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20031204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040219

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040824

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20041221